Buy Day today: Good (67) Broad market participation · no major macro event

Halozyme Therapeutics Inc (HALO)

Healthcare Biotechnology

82.30 $

-0.3% vs. previous close

Closing price · As of: 3. Aug 2026

Halozyme Therapeutics Inc (HALO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 2,525 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow

Annual Quarterly

All figures in millions of USD.

Balance Sheet HALO
Tick rows to compare them in a chart (up to 4)	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	166	182	262	520	440	566	580	1,104	1,842	1,733	2,063	2,525
Current Assets	161	172	257	510	428	543	555	926	739	746	1,085	825
Cash	61	43	67	169	58	120	148	119	234	118	116	134
Cash & Short-Term Investments	136	108	205	469	355	421	368	741	363	336	596	143
Receivables	9.1	32	16	22	30	59	98	91	231	234	308	441
Inventory	6.4	9.5	15	5.1	23	29	61	54	100	128	142	176
Property, Plant & Equipment	3.0	3.9	4.3	3.5	7.5	11	11	8.8	76	–	–	–
Goodwill	0.0	0.0	0.0	0.0	–	–	–	0.0	409	417	417	580
Intangible Assets	0.0	0.0	0.0	0.0	–	–	–	–	547	473	402	981
Total Liabilities	125	139	294	312	191	474	429	907	1,672	1,649	1,700	2,477
Current Liabilities	24	62	55	131	149	86	421	117	131	112	139	177
Short-Term Debt	50	22	17	77	92	20	397	89	13	6.6	–	–
Accounts Payable	3.0	4.5	3.6	7.9	4.1	6.4	1.9	1.5	18	12	10	21
Long-Term Debt	50	28	199	125	35	383	–	787	1,493	1,499	1,506	2,143
Shareholders' Equity	41	43	-32	208	249	92	151	197	170	84	364	49
Retained Earnings	-450	-483	-585	-522	-531	-604	-475	-59	143	91	360	55
Shares Outstanding	123	127	128	139	144	144	141	147	141	134	129	124

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cookie settings